Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines
| Autor: | Santini, V, Alessandrino, Pe, Angelucci, E, Barosi, G, Billio, A, DI MAIO, Massimo, Finelli, C, Locatelli, F, Marchetti, M, Morra, E, Musto, P, Visani, G, Tura, S, Italian Society of Hematology |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Adolescent Juvenile myelomonocytic leukaemia MEDLINE Antineoplastic Agents Iron chelation medicine Overall survival Humans Child Intensive care medicine Lenalidomide Refractory anaemia business.industry Myelodysplastic syndromes Hematology Middle Aged medicine.disease Thalidomide Graft versus leukaemia Oncology Child Preschool Myelodysplastic Syndromes business medicine.drug |
| Zdroj: | Leukemia Research. 34:1576-1588 |
| ISSN: | 0145-2126 |
| DOI: | 10.1016/j.leukres.2010.01.018 |
| Popis: | Since 2002, date of publication of the previous Italian Society of Haematology (SIE) practice guidelines for management of myelodysplastic syndromes (MDS), novel disease-modifying treatments have been introduced and the SIE commissioned an update. After a comprehensive review of the medical literature published since January 2001, the Expert Panel formulated recommendations for the management of adult and paediatric MDS, graded according to the available evidence. The major updates are: first-line hypomethylating agents in patients with INT2-high-risk disease; controlled use of first-line lenalidomide in low-INT1 risk transfusion-dependent patients with 5q deletion; deferasirox in low-INT1 patients with a relevant transfusional load; first-line high-dose ESA in low-INT1 patients with Hb10 g/dl and endogenous EPO500 U/l; allogeneic HSCT first-line therapy for INT2- and high-risk patients65 years without severe co morbidities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect